Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

Conoce a Laurel Crosby, PhD, miembro del equipo SGTC

En este  #OMFScienceWednesday tenemos el honor de presentaros a Laurel Crosby, PhD,  quien fue la primera miembro del Stanford Genome Technology Center (SGTC)  en unirse a Dr. Ron Davis en su misión de entender la base molecular de EM/SFC. Laurel ha compartido su historia con OMF.

Laurel Crosby, PhD, miembro del equipo SGTC

“Mi nombre es Laurel Crosby, Ph.D, y soy investigadora de ingeniería asociada al Stanford Genome Technology Center. Mi experiencia se centra en biología,  ecología microbiana, ingeniería ambiental y desarrollo de tecnología de diagnostico molecular.

Ayudé a Ron Davis a establecer el laboratorio del SFC Research Center a Stanford, y mi título oficial es  Directora de Innovación. Paso la mitad de mi tiempo pensando como una científica, buscando pistas, revisando nuevas tecnologías e identificando nuevas vías para mejorar la calidad de vida para los pacientes y sus familias.

Estoy centrada en la interacción entre genética y el medioambiente, especialmente nutrición, el microbiomo y exposiciones medioambientales. Mi experiencia en ingeniería me da la habilidad de mirar  la salud como una red de interacciones, y me centro en metabólomica y genética como parte del componente Multi-Omics de nuestra programa de investigación.

También estoy trabajando actualmente en estrategias para evaluar la exposición a metales pesados  y maneras más precisas de medir trazas de metales esenciales dentro de las células y tejidos.

El resto de mi tiempo, lo paso como ‘la arregladora’. Aseguro que las cosas se hacen sin problemas y apoyo el resto del equipo de investigación de EM/SFC en el SGTC.

Por ejemplo, cuando tuvimos necesidad de muestras de pacientes, escribí los protocolos del IRB (Panel de Revisión Independiente) y establecí los servicios de flebotomía. Cuando encontré una tecnología prometedora, negocié con compañías para proveer demostraciones de equipamiento y precios favorables.

Ahora mismo, estoy trabajando en facilitar el acceso a nuestras herramientas de precisión y servicios a  médicos y pacientes. Siempre intento encontrar una manera para que las cosas funcionen y cuesten menos.

En 2012, Ron y yo fuimos las únicas personas en la Stanford Genome Technology Center interesados en estudiar EM/SFC y ahora somos un centro con enorme actividad con más de una docena de investigadores, varios proyectos interesantes y muchas colaboraciones domésticas e internacionales.”

Gracias Laurel, por tu compromiso firme, valiente y persistente con nuestra misión de ayudar a pacientes a recuperar por completo a sus vidas. #EndMECFS

Puedes encontrar más sobre este articulo en nuestra página web: http://bit.ly/2vIAG7D

Gracias a Teresa por la traducción.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo